Chemistry:Evocalcet
From HandWiki
Short description: Chemical compound
Clinical data | |
---|---|
Trade names | Orkedia |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C24H26N2O2 |
Molar mass | 374.484 g·mol−1 |
Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism.[1] It acts as a calcium-sensing receptor agonist.[2]
In 2018, it was approved in Japan for treatment of secondary hyperparathyroidism in patients on dialysis.[3]
References
- ↑ "A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro". PLOS ONE 13 (4): e0195316. 2018. doi:10.1371/journal.pone.0195316. PMID 29614098. Bibcode: 2018PLoSO..1395316K.
- ↑ "Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism". Bioorganic & Medicinal Chemistry Letters 28 (11): 2055–2060. June 2018. doi:10.1016/j.bmcl.2018.04.055. PMID 29724589.
- ↑ "Kyowa Hakko Kirin Launches Orkedia Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan" (Press release). Kyowa Hakko Kirin. May 22, 2018.
Original source: https://en.wikipedia.org/wiki/Evocalcet.
Read more |